BRIDGE POINT CAPITAL
Western Governance, Asia Play
Dr. Makarand Jawadekar | Advisor
Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at Pfizer Inc. in Groton-New London, Connecticut, for 28 consecutive years. His most recent position was as a Director of Portfolio Management at Pfizer Inc. In the recent past, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. In February 2011, Mak was honored with an honorary D.Sc. degree from DYP Mumbai University, recommended by the President of India.
His 28+ years of experience with Pfizer Global R&D specifically includes Solids R&D, Drug Product formulation/ Dosage Form/ Drug Delivery development, Clinical Trials Supply Manufacturing, Scale-up and Technology Transfer & Research Pharmacy functions. He helped create various Pharma R&D Partnerships, JVs, and Collaborations. He managed several functions/groups within R&D for many years.
As a “Bench Scientist”, he touched upon many challenging commercial formulations which became multibillion-dollar products for many years for Pfizer Inc. These R&D formulations & Product development programs included ZOLOFT, ZITHROMAX, VIAGRA faster onset & other successful products. He also worked on several “Life Cycle Management “projects for Pfizer’s existing ethical & OTC products. After retiring from Pfizer, he had an opportunity to work with KKR, a Private Equity group in New York, for acquisition of Capsugel division from Pfizer which Pfizer divested in 2011. Mak has presented at many professional meetings and has participated in various Panel Discussions/Round Tables around the globe during his Pfizer tenure. He currently serves on various Biotech/ Pharma company advisory boards and Boards of Directors.